EMN 2021 | BVD in heavily pretreated multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the use of bendamustine plus bortezomib and dexamethasone (BVD) in patients with heavily pretreated multiple myeloma. A retrospective analysis of real-world data from 81 patients with relapsed/refractory multiple myeloma who had received salvage therapy with BVD, demonstrated an overall response rate of 63%, with seven patients achieving a complete response and 18 patients achieving a very good partial response. 19 patients achieved stable disease. Dr Cerchione reports that BVD has shown potential as a good bridging therapy for second autologous or allogeneic stem cell transplantation and after failure of novel agents. This interview took place during the 2021 European Myeloma Network (EMN) congress.
